Χειρουργική γλαυκώματος: Ποιο εμφύτευμα είναι πιο αποτελεσματικό και από ποια βαλβίδα

Learning ObjectivesAfter watching this webinar, participants will be able to:Describe the mechanisms of action for transthyretin (TTR) stabilisers, silencers, antibodies, and genome editing therapies in the context of ATTR amyloidosis.Recognise how each therapeutic approach influences amyloid formation or promotes amyloid clearance.Needs assessment and expected educational outcomeTo appreciate how therapies target different steps in the amyloid cascade.This webinar is part of the Bench to Bedside Webinar series dedicated to Amyloidosis (link available soon).You may also register for the two upcoming webinars in this series:Amyloidosis : Clinical Trial Evidence Across Therapeutic Classes in ATTR-CMAmyloidosis : Treatment Sequencing and Patient Selection in the Era of Multiple ATTR TherapiesMain topic:Myocardial Disease - Clinical - Infiltrative Myocardial Disease - Cardiac AmyloidosisSession informationThis webinar is designed for:General practicing cardiologists and trainees seeking to better understand the impact of trials’ results on their day-to-day practice and stay informed with the most up to date and foundational knowledge of a certain topic (core cardiology level).Cardiologist specialists seeking a better understanding of the key advancements in trials, both inside and outside their main area of expertise (subspecialty level).The wide cardiovascular community of nurses and allied professionalsResearchers and academics in the field of cardiology.During the webinar, you will be encouraged to send your questions by chat and interact with our key opinion leaders who will provide live feedback.Technical settingsThe webinar is available on PC and tablets. The use of a smartphone is not recommended.To answer the MCQs during the live, you must allow pop-up windows.A high-speed Internet connection is required (minimum 2 Mbps).An application has been made to the EACCME® for CME accreditation of this event.

On behalf of the Executive Committee, IFCN, I am delighted to welcome you to the 34th International Congress of Clinical Neurophysiology. It is a pleasure to visit Cartagena, the first visit of an ICCN to Colombia and a reflection of the IFCN’s aim to spread best practice and education in Clinical Neurophysiology widely throughout the world.Our scientific committee, co-chaired by Professors Tankisi and Guterriez, will be working hard to combine recent advances in research with the best clinical teaching to provide a congress of both breadth and depth. The ICCN is also an opportunity to work with our colleagues in the ACME and others from the Latin American Chapter. One of the real pleasures of IFCN work is this interaction with those who begin as colleagues and then become friends.It must also be said that this opportunity to come to Cartagena with its rich colonial history and Caribbean aspect is part of the appeal. In addition to the excellent lectures, symposia and workshops, we hope you will all be able to explore the old town and the coast. Our ICCNs are primarily but not exclusively about work. So, please submit something for the congress, or come to learn. But also find time for the beauty and history of the area and take part in the exciting social programme being developed. In this way we can all learn more of our wonderful specialty but also enjoy the chance for some to meet old friends and for younger colleagues to form those collaborations which then themselves become friendships.Please join us for the best of Clinical Neurophysiology in a unique and beautiful part of Colombia.

Dear EANO members, colleagues and friends,The 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) will be held in Rome (Italy). The annual EANO meeting will kick off with a multiprofessional interdisciplinary Educational Day with separate tracks on Thursday, September 24 and the main scientific program will commence on Friday, September 25. The congress fosters exchange and collaboration between all stakeholders at all career stages in the field of neuro-oncology with students and professional experts in clinical and basic neuro-oncology, neurosurgery, neuropathology, neuroradiology and radiation oncology as well as nursing and other allied health professionals. It aims to bring together scientific and clinical expertise to bridge gaps in our understanding and management of nervous system tumors.EANO is Europe’s multidisciplinary neuro-oncology organisation representing all medical and scientific disciplines involved in the prevention, diagnosis, and treatment of tumors of the central and peripheral nervous system including neurology, neurosurgery, radiation oncology, medical oncology, pediatric neuro-oncology, neuropathology complemented by a vibrant basic science community. The successful 2025 EANO meeting in Prague attracted more than 1500 participants from all continents and was very highly rated!Throughout the congress, speakers from around the world will share the latest clinical trial results, as well as key innovations in neuro-oncology, from basic science breakthroughs and advances in precision diagnostics to innovative local and systemic treatment modalities.Save the date for Europe's largest neuro-oncology congress that attracts participants from all over the world!

The conference sets the stage for the dissemination and exchange of new developments in diverse, emerging fields within chemical biology. It is the largest and longest-standing conference in the field, being a platform for inspiration, collaboration, and networking for researchers in academia and industry.We aim to provide the possibility for every chemical biologist to meet and discuss with peers topics ranging from tool development to biological applications, from computational protein design to new drug modalities.